Transporter molecules influence the gene expression in HeLa cells

International Journal of Medical Sciences

Volumn 6, Issue 1, 2009, Pages 18-27

  Waldeck, Waldemar ^a   Pipkorn, Ruediger ^a   Korn, Bernhard ^a   Mueller, Gabriele ^a   Schick, Matthias ^a   Tóth, Katalin ^a   Wiessler, Manfred ^a   Didinger, Bernd ^b   Braun, Klaus ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Carrier molecules; Drug delivery; Facilitated transport; Transport peptides

Indexed keywords

CARRIER PROTEIN; PROTEIN KINASE N; PROTEIN KINASE N1; UNCLASSIFIED DRUG;

ARTICLE; BIOINFORMATICS; CONTROLLED STUDY; GENE EXPRESSION; GENE LOCUS; HELA CELL; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PHYSICAL CHEMISTRY; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 60149098616     PISSN: None     EISSN: 14491907     Source Type: Journal    
DOI: 10.7150/ijms.6.18     Document Type: Article

References (47)

1. Boucher R. Current status of CF gene therapy. Trends Genet. 1999; 12: 81-4.
2. Anson DS. The use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery. Genet Vaccines Ther. 2004; 2: 9.
3. Lu Y, Choi YK, Campbell-Thompson M, et al. Therapeutic level of functional human alpha 1 antitrypsin (hAAT) secreted from murine muscle transduced by adeno-associated virus (rAAV1) vector. J Gene Med. 2006; 8: 730-5.
4. Edelstein ML, Abedi MR, Wixon J, et al. Gene therapy clinical trials worldwide 1989-2004-an overview. J Gene Med. 2004; 6: 597-602.
5. Chuah MK, Collen D, VandenDriessche T. Gene therapy for hemophilia. J Gene Med. 2001; 3: 3-20.
6. Cavazzana-Calvo M, Fischer A. Gene therapy for severe combined immunodeficiency: are we there yet? J Clin Invest. 2007; 117: 1456-65.
7. Amalfitano A. Next-generation adenoviral vectors: new and improved. Gene Therapy. 1999; 6: 1643-5.
8. Armeanu S, Ungerechts G, Bernloehr C, et al. Cell cycle independent infection and gene transfer by recombinant Sendai viruses. J Virol Methods. 2003; 108: 229-33.
9. Hale SJ and Green NK. Viral approaches to cancer gene therapy. Expert Opin Ther Patents 2002. 12(3): 369-378.
10. Dobbelstein M. Viruses in therapy-royal road or dead end? Virus Res. 2003; 92: 219-21.
11. Robbins PD, Ghivizzani SC. Viral vectors for gene therapy. Pharmacol Ther. 1998; 80: 35-47.
12. Lechardeur D, Lukacs GL. Intracellular barriers to non-viral gene transfer. Curr Gene Ther. 2002; 2: 183-94.
13. Christiaens B, Grooten J, Reusens M, et al. Membrane interaction and cellular internalization of penetratin peptides. European Journal of Biochemistry. 2004; 271: 1187-97.
14. Silhol M, Tyagi M, Giacca M, et al. Different mechanisms for cellular internalization of the HIV-1 Tat-derived cell penetrating peptide and recombinant proteins fused to Tat. Eur J Biochem. 2002; 269: 494-501.
15. Vives E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem. 1997; 272: 16010-7.
16. Console S, Marty C, Garcia-Echeverria C, et al. Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans. J Biol Chem. 2003; 278: 35109-14.
17. Koppelhus U, Awasthi SK, Zachar V, et al. Cell-dependent differential cellular uptake of PNA, peptides, and PNA- peptide conjugates. Antisense Nucleic Acid Drug D. 2002; 12: 51-63.
18. Giovannangeli C, Diviacco S, Labrousse V, et al. Accessibility of nuclear DNA to triplex-forming oligonucleotides: the integrated HIV-1 provirus as a target. Proc Natl Acad Sci U S A. 1997; 94: 79-84.
19. Jarver P, Langel U. The use of cell-penetrating peptides as a tool for gene regulation. Drug Discov Today. 2004; 9: 395-402.
20. Schwarze SR, Hruska KA, Dowdy SF. Protein transduction: unrestricted delivery into all cells? Tr Cell Biol. 2000; 10: 290-5.
21. Fawell S, Seery J, Daikh Y, et al. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci U S A. 1994; 91: 664-8.
22. Elliott G, O'Hare P. Intercellular trafficking of VP22-GFP fusion proteins. Gene Ther. 1999; 6: 149-51.
23. Phelan A, Elliott G, O'Hare P. Intercellular delivery of functional p53 by the herpesvirus protein VP22 [see comments]. Nat Biotechnol. 1998; 16: 440-3.
24. Derossi D, Chassaing G, Prochiantz A. Trojan peptides: the penetratin system for intracellular delivery. Tr Cell Biol. 1998; 8: 84-7.
25. Lundberg P, Langel U. A brief introduction to cell-penetrating peptides. Journal of Molecular Recognition. 2003; 16: 227-33.
26. Duchardt F, Fotin-Mleczek M, Schwarz H, et al. A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic. 2007; 8: 848-66.
27. Wender PA, Galliher WC, Goun EA, et al. The design of guanidinium-rich transporters and their internalization mechanisms. Adv Drug Deliv Rev. 2008; 60: 452-72.
28. Joliot A, Le Roux I, Volovitch M, et al. Neurotrophic activity of an homeobox peptide. Ann Genet. 1993; 36: 70-2.
29. Dom G, Shaw-Jackson C, Matis C, et al. Cellular uptake of Antennapedia Penetratin peptides is a two-step process in which phase transfer precedes a tryptophan-dependent translocation. Nucleic Acids Res. 2003; 31: 556-61.
30. Schwartz JJ, Zhang S. Peptide-mediated cellular delivery. Curr Opin Mol Ther. 2000; 2: 162-7.
31. Vives E, Richard JP, Rispal C, et al. TAT peptide internalization: Seeking the mechanism of entry. Current Protein & Peptide Science. 2003; 4: 125-32.
32. Song Y, Tong Z, Wang J, et al. Complete genome sequence of Yersinia pestis strain 91001, an isolate avirulent to humans. DNA Res. 2004; 11: 179-97.
33. Ulbrich K, Pechar M, Strohalm J, et al. Synthesis of biodegradable polymers for controlled drug release. Ann N Y Acad Sci. 1997; 831: 47-56.
34. Kopecek J, Kopeckova P, Minko T, et al. HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur J Pharm Biopharm. 2000; 50: 61-81.
35. Kopecek J, Kopeckova P, Minko T, et al. Water soluble polymers in tumor targeted delivery. Journal of Controlled Release. 2001; 74: 147-58.
36. Gray JW, Collins C. Genome changes and gene expression in human solid tumors. Carcinogenesis. 2000; 21: 443-52.
37. Merriefield RB. Solid Phase Peptide Synthesis. I The Synthesis of a Tetrapeptide. J Americ Chem Soc. 1963; 85: 2149-54.
38. Carpino LA, Ionescu D, El Faham A, et al. Complex polyfluoride additives in Fmoc-amino acid fluoride coupling processes. Enhanced reactivity and avoidance of stereomutation. Org Lett. 2003; 5: 975-7.
39. Lammers T, Peschke P, Kuhnlein R, et al. Effect of intratumoral injection on the biodistribution and the therapeutic potential of HPMA copolymer-based drug delivery systems. Neoplasia. 2006; 8: 788-95.
40. Van Gelder RN, von Zastrow ME, Yool A, et al. Amplified RNA synthesized from limited quantities of heterogeneous cDNA. Proc Natl Acad Sci U S A. 1990; 87: 1663-7.
41. Wiley SE, Murphy AN, Ross SA, et al. MitoNEET is an iron-containing outer mitochondrial membrane protein that regulates oxidative capacity. Proc Natl Acad Sci U S A. 2007; 104: 5318-23.
42. Paddock ML, Wiley SE, Axelrod HL, et al. MitoNEET is a uniquely folded 2Fe 2S outer mitochondrial membrane protein stabilized by pioglitazone. Proc Natl Acad Sci U S A. 2007; 104: 14342-7.
43. Lartey J, Smith M, Pawade J, et al. Up-regulation of myometrial RHO effector proteins (PKN1 and DIAPH1) and CPI-17 (PPP1R14A) phosphorylation in human pregnancy is associated with increased GTP-RHOA in spontaneous preterm labor. Biol Reprod. 2007; 76: 971-82.
44. Madigan MC, Kingsley EA, Cozzi PJ, et al. The role of extracellular matrix metalloproteinase inducer protein in prostate cancer progression. Cancer Immunol Immunother. 2008; 57: 1367-79.
45. Beesley AH, Weller RE, Kees UR. The role of BSG (CD147) in acute lymphoblastic leukaemia and relapse. Br J Haematol. 2008 142(6):1000-2.
46. Millimaggi D, Mari M, D'Ascenzo S, et al. Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells. Neoplasia. 2007; 9: 349-57.
47. Ju XZ, Yang JM, Zhou XY, et al. EMMPRIN expression as a prognostic factor in radiotherapy of cervical cancer. Clin Cancer Res. 2008; 14: 494-501.